Practical AI for CEOs


The AI race is on. CEOs recognise it as the new force multiplier. AI has the potential to both reshape productivity and drive commercial effectiveness. This report by Criticaleye Partner AlixPartners provides a guide to help manage an array of competing stakeholder demands and develop your understanding and capabilities.
 
Key Takeaways Include:
  • Your data is one of your most valuable assets - make it work for you.
  • A fear of missing out and a herd mentality can disproportionately influence technology investments in the current market, potentially leading to poor returns.
  • Deep experience in dealing with business problems, combined with AI insights, drives the kind of actionable results that customers demand.

Share this with your Community





Click here to download this insight

DOWNLOAD INSIGHT



Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.


Click here to download this insight

Where M&A Value is Won or Lost

M&A can create significant opportunities for growth, but realising the expected value often depends on how effectively organisations manage the people side of a transaction. This report by LACE Partners explores how...


Click here to download this insight

VIEWPOINTS | Five Leadership Lessons with Thomas Wellauer

Few leaders have occupied as many different seats as Thomas Wellauer. Across four decades, he has been a Senior Partner at McKinsey & Company, CEO of Credit Suisse Financial Services, Executive Board member at No...


Click here to download this insight

The Tech Making CPOs Go Faster

As the HR function evolves, technology investment decisions have become a marker of ambition and maturity, not just efficiency. But talk to CPOs at the sharp end of these decisions and a more complicated picture emer...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 239




Stream Lightsource bp Drax Group plc E.ON UK NATS Global Payments London Stock Exchange Group Rolls-Royce AlixPartners British Land NatWest Group Hitachi Solutions GlaxoSmithKline plc LACE Partners Mayborn Group Legal & General